Table 1.
Patient characteristics at baseline
| All (n = 409) |
irAEs ( +) (n = 138) |
irAEs (-) (n = 271) |
P value | |
|---|---|---|---|---|
| Age, years | 69 (60–74) | 70 (60–74) | 69 (60–74) | 0.32 |
| Gender (male) | 288 (70.4) | 94 (68.7) | 194 (71.6) | 0.49 |
| BMI, kg/m2 | 20.9 (18.1–23.4) | 21.7 (18.5–24.0) | 20.5 (17.9–23.2) | 0.04 |
| Pulse rate, bpm | 82 (73–93) | 81 (71–91) | 84 (74–94) | 0.12 |
| Systolic blood pressure, mmHg | 120 (107–134) | 123 (111–134) | 118 (106–133) | 0.14 |
| Diastolic blood pressure, mmHg | 72 (64–81) | 72 (64–81) | 72 (64–82) | 0.70 |
| Cancer type | ||||
| Non-small cell lung cancer | 170 (41.6) | 59 (42.8) | 111 (41.0) | 0.75 |
| Malignant melanoma | 82 (20.0) | 42 (30.4) | 40 (14.8) | < 0.01 |
| Renal cancer | 43 (10.5) | 20 (14.5) | 23 (8.5) | 0.09 |
| Stomach cancer | 35 (8.6) | 4 (2.9) | 31 (11.4) | 0.003 |
| Pharyngeal cancer | 21 (5.1) | 3 (2.2) | 18 (6.6) | 0.059 |
| Paranasal cancer | 7 (1.7) | 2 (1.4) | 5 (1.8) | 1 |
| Tongue cancer | 7 (1.7) | 1 (0.7) | 6 (2.2) | 0.43 |
| Bladder cancer | 6 (1.5) | 1 (0.7) | 5 (1.8) | 0.67 |
| Mesothelioma | 5 (1.2) | 0 (0) | 5 (1.8) | 0.17 |
| Other cancer | 33 (8.1) | 6 (4.3) | 27 (10.0) | 0.056 |
| Comorbidity | ||||
| Hypertension | 162 (39.6) | 60 (43.5) | 102 (37.6) | 0.29 |
| Diabetes mellitus | 74 (18.1) | 27 (19.6) | 47 (17.3) | 0.59 |
| Dyslipidemia | 72 (17.6) | 31 (22.5) | 41 (15.1) | 0.075 |
| Cardiovascular history | ||||
| Coronary artery disease | 34 (8.3) | 15 (10.9) | 19 (7.0) | 0.19 |
| Arrythmia | 24 (5.9) | 11 (8.0) | 13 (4.8) | 0.27 |
| Heart failure | 5 (1.2) | 2 (1.4) | 3 (1.1) | 1 |
| Venous thrombosis | 8 (2.0) | 0 (0) | 8 (3.0) | 0.06 |
| Pericardial disease | 3 (0.7) | 0 (0) | 3 (1.1) | 0.55 |
| Medication | ||||
| ACE-I/ARB | 81 (19.8) | 35 (25.4) | 47 (17.3) | 0.067 |
| Beta-blockers | 34 (8.3) | 15 (10.9) | 19 (7.0) | 0.26 |
| Ca-channel blockers | 118 (28.9) | 43 (31.2) | 75 (27.7) | 0.49 |
| Statins | 57 (13.9) | 23 (16.7) | 34 (12.5) | 0.29 |
| Diuretics | 28 (6.8) | 6 (4.3) | 27 (10.0) | 0.21 |
| Laboratory measurements | ||||
| TP, mg/dL | 6.8 (6.3–7.1) | 6.8 (6.5–7.0) | 6.7 (6.3–7.2) | 0.37 |
| Alb, mg/dL | 3.7 (3.3–4.0) | 3.8 (3.4–4.1) | 3.7 (3.2–4.0) | 0.01 |
| Cre, mg/dL | 0.79 (0.65–1.00) | 0.78 (0.64–1.00) | 0.79 (0.65–1.00) | 0.91 |
| CRP, md/dL | 0.42 (0.10—1.80) | 0.23 (0.07—1.12) | 0.56 (0.13 – 2.28) | 0.004 |
| WBC, /103 | 6.0 (4.9—7.7) | 5.9 (4.9 – 7.3) | 6.0 (4.9—7.8) | 0.44 |
| Hb, mg/dL | 11.8 (10.4–13.0) | 12.0 (10.9–13.2) | 11.7 (10.3–12.9) | 0.033 |
| Chest radiography | ||||
| CTR, % | 46.5 (42.6–50.1) | 46.8 (42.8–50.2) | 46.3 (42.5–50.1) | 0.56 |
irAEs immune-Related Adverse Events, BMI body mass index, ACE-I angiotensin-converting-enzyme inhibitor, ARB Angiotensin II Receptor Blocker, TP total protein, Alb albumin, Cre creatinine, CRP C-reactive protein, WBC white blood cell, Hb hemoglobin, CTR cardiothoracic ratio